Tenet Healthcare Corporation
NYSE:THCMedical - Care Facilities
-$5.06 today
- Market cap
- $21.60B
- Beta
- 1.28
- P/E (TTM)
- 9.1
- EPS (TTM)
- $19.62
Volume 1.57M
Average 1.41M
THC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Tenet Healthcare CorporationNYSE: THC
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $1.24B rose 17.3% year over year, ahead of the +9.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 20.9% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.
Context
- EBITDA amounted to 21.0% of revenue in FY2025, down 12.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 14 analysts of $4.28B (-4.5%) for the fiscal year ending Dec 2026, a step up from the -34.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.24B-20.9% QoQ
- Last fiscal yearDec 2025
- $4.48B-34.9% YoY
- LTMJun 2026
- $5.06B+9.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.3% | -21.0% | -38.4 pp |
| 1 year | -34.9% | -4.5% | +30.4 pp |
| 3-year CAGR | +13.4% | -1.3% | -14.7 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 4.48B USD
- Year-over-year change
- -34.9%
- 4-year CAGR
- +5.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.48B | -34.9% |
| FY2024 | 2024-12-31 | 6.89B | +103.4% |
| FY2023 | 2023-12-31 | 3.39B | +10.1% |
| FY2022 | 2022-12-31 | 3.08B | -16.1% |
| FY2021 | 2021-12-31 | 3.67B | — |
EBITDA vs competitors
How THC compares with its peers on the latest reported figures
- THC's LTM Jun 2026 EBITDA of $5.06B is the 2nd highest of the 7 companies compared; the peer median is $1.74B.
- Its year-over-year change of +9.6% is the 5th highest of 7, against a peer median of +13.2%.
- EBITDA amounts to 23.2% of revenue for THC, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $15.84B | +10.3% | +5.5% | 20.3% | |
| LTM Jun 2026 | $5.06B | +9.6% | +13.4% | 23.2% | |
| LTM Mar 2026 | $4.96B | +296.6% | +20.0% | 23.1% | |
| LTM Jun 2026 | $2.82B | +16.2% | +20.3% | 15.6% | |
| LTM Sep 2026 | $667.4M | -18.3% | +7.1% | 19.9% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $505.76M | -10.5% | -2.2% | 7.9% |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $478.53M | +19.3% | +7.4% | 20.5% |
| Peer median (excluding THC) | $1.74B | +13.2% | +7.3% | 20.1% | |
Competitors are the stored peer set for THC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.49B | 19.17B | 20.55B | 20.67B | 21.31B |
| Cost of Revenue | 12.22B | 12.13B | 12.74B | 12.46B | 3.78B |
| Gross Profit | 7.27B | 7.05B | 7.81B | 8.21B | 17.53B |
| Gross Margin | 37.3% | 36.8% | 38.0% | 39.7% | 82.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 412M | 412M | 418M | 8.8B | 8.71B |
| Operating Expenses | 4.4B | 4.72B | 5.3B | 2.25B | 14.09B |
| Depreciation & Amortization | 855M | 841M | 870M | 818M | 863M |
| EBITDA | 3.67B | 3.08B | 3.39B | 6.89B | 4.48B |
| EBITDA Margin | 18.8% | 16.0% | 16.5% | 33.4% | 21.0% |
| Operating Income | 2.87B | 2.33B | 2.51B | 5.96B | 3.44B |
| Operating Margin | 14.7% | 12.2% | 12.2% | 28.8% | 16.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 923M | 890M | 901M | 826M | 821M |
| Other Income / Expenses | (983M) | (988M) | (893M) | (708M) | (639M) |
| Income Before Tax | 1.89B | 1.35B | 1.62B | 5.25B | 2.8B |
| Pre-Tax Margin | 9.7% | 7.0% | 7.9% | 25.4% | 13.1% |
| Income Tax Expense | 411M | 344M | 306M | 1.18B | 433M |
| Net Income | 914M | 411M | 611M | 3.2B | 1.41B |
| Net Margin | 4.7% | 2.1% | 3.0% | 15.5% | 6.6% |
| EPS (Basic) | 8.55 | 3.84 | 6.01 | 33.02 | 15.61 |
| EPS (Diluted) | 8.42 | 3.79 | 5.71 | 32.70 | 15.49 |
| Weighted Avg Shares | 106.83M | 106.93M | 101.64M | 96.9M | 90.15M |
| Weighted Avg Shares (Diluted) | 108.57M | 110.52M | 104.8M | 97.88M | 90.83M |
Tenet Healthcare Corporation
NYSE:THC
Intrinsic Alpha fair value
Locked
Current Price
$271.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.